Fewer eye needles? Higher-Dose aflibercept shows promise for wet AMD

NCT ID NCT07423429

Recruiting now Disease control Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at switching people with wet age-related macular degeneration (AMD) to a higher dose (8 mg) of the drug aflibercept. The goal is to see if it can extend the time between eye injections while still controlling the disease. Researchers will compare injection intervals, vision outcomes, and safety before and after the switch in about 100 patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: aflibercept 8 mg (a higher dose of an anti-VEGF drug given as an eye injection)
What this could lead to: If successful, this could mean fewer eye injections for people with wet age-related macular degeneration, reducing treatment burden while maintaining disease control.
What could go wrong: This is a small, retrospective observational study, not a controlled trial. Results may not prove cause and effect, and the higher dose might not work for everyone or could have unknown side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXUDATIVE AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXUDATIVE AGE-RELATED MACULAR DEGENERATION

Contacts and locations

Locations

CHU Nantes - Ophthalmology Department
RECRUITING

Nantes, Nantes, 44000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.